Key result
HCN4 is the principal isoform underlying the sino-atrial pacemaker current, and its genetic deletion or pharmacological inhibition demonstrates its essential role in setting basal heart rate and stabilizing cardiac rhythm.
This review highlights the role of HCN channels in cardiac pacemaking and the therapeutic potential of HCN channel blockers like ivabradine in stable angina and heart failure.
May inform selective HCN4-targeted rate control; leaves open translation from mouse models to clinical trials.
Hyperpolarization-activated cation channels generate the I(f) current in the heart. In the sino-atrial node (SAN), I(f) is thought to play an essential role in setting the heart rate and mediating its autonomic control. This review focuses on the role of I(f) in pacemaking and non-pacemaking cardiomyocytes and the resulting therapeutic implications. HCN4 represents the principal isoform underlying sino-atrial I(f) , but other isoforms may also be of importance. To examine the functional role of cardiac channels, several mouse mutants, most of them targeting HCN4, have been generated by different groups. Unexpectedly, these lines display greatly different and as yet unexplained phenotypes. We provide an overview about these HCN mutants and suggest an interpretation of the functional significance of I(f) in the SAN in light of these studies. HCN channels are also present in ventricular myocytes, and an up-regulation of I(f) in the hypertrophic and failing heart may contribute to arrhythmogenesis. Inhibition of I(f) by HCN channel blockers is a novel approach in the treatment of cardiac disorders, and ivabradine is approved for treatment of stable angina pectoris. Remarkably, a recent clinical trial assessing this substance in heart failure showed a significantly improved outcome. The mechanism underlying this beneficial effect is not yet clear and might lie beyond heart rate slowing. Thus, the growing knowledge about cardiac HCN channels will undoubtedly promote the development of the promising class of HCN channel blockers.
No takes yet. Share an insight, caveat, or question.
Herrmann et al. (2011) conducted a review in Cardiac arrhythmias and heart failure. HCN channel mutations and blockers was evaluated. HCN4 is the principal isoform underlying the sino-atrial pacemaker current, and its genetic deletion or pharmacological inhibition demonstrates its essential role in setting basal heart rate and stabilizing cardiac rhythm.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: